Optimal Balance Pharmacy Recalls Compounded Glutathione Vials After Elevated Endotoxin Levels Detected

Elevated bacterial endotoxin in a compounded injectable product has triggered a patient-level recall by Optimal Balance Pharmacy, a Houston-based compounder, underscoring the sterility assurance risks inherent to multi-dose vial formats and the endotoxin testing controls regulators expect from 503A operations. The recall, announced August 19, 2026, covers one lot of Glutathione Injection 200 mg/mL (30 mL) Multi-Dose Vials (Lot LG342009076, expiry October 4, 2026).

The pharmacy's own testing identified the out-of-specification endotoxin result, prompting voluntary action before FDA-initiated enforcement. That sequence matters: internal detection is the expected outcome of a functioning quality system, yet the presence of elevated endotoxin in a released lot points to a breakdown earlier in the process, whether in LAL testing frequency, raw-material qualification, or in-process controls for the compounding environment. Adverse events have already been reported, including fever, chills, severe headache, nausea, vomiting, pain, and symptoms consistent with allergic reaction, confirming patient exposure occurred before the recall was initiated.

Distribution reached consumers across 14 states: Arizona, Colorado, Florida, Illinois, Louisiana, Michigan, New York, Nevada, Oklahoma, Pennsylvania, Texas, Utah, Vermont, and Washington. The geographic spread of a single compounded lot to that many jurisdictions will draw attention from FDA's Office of Pharmaceutical Quality, particularly as the agency continues to tighten oversight of compounders operating under 21 CFR Part 503A. Multi-dose vials compound the sterility assurance challenge relative to single-dose formats: repeated puncture events, extended in-use periods, and larger fill volumes each represent additional endotoxin ingress vectors that demand robust container-closure integrity and preservative efficacy data.

For QA directors at compounding facilities, the recall is a direct prompt to audit LAL testing protocols, confirm that endotoxin limits are set against the product's route of administration and maximum dose, and verify that environmental monitoring data for the compounding suite is trending within alert and action limits. Facilities that have not recently reviewed their endotoxin specification against current USP <85> requirements and ICH Q6A principles are carrying unquantified risk.

Optimal Balance Pharmacy is retrieving product via direct outreach to prescribers and patients by telephone and mail, with full refunds offered for unreimbursed units; adverse events should be reported through FDA's MedWatch program.

The lot's October 4, 2026 expiry means recalled units remain within shelf life, making complete retrieval from the 14-state distribution footprint the immediate measurable outcome regulators will track.

Source: U.S. Food and Drug Administration recalls database via FDA.gov RSS Feed, August 20, 2026.